[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Porzezińska M, Drozdowski J, Poławska K, Wolska-Goszka L, Cynowska B, Słomiński JM: [Isolated sarcoidosis of upper respiratory tract--a description of 2 cases]. Pneumonol Alergol Pol; 2008;76(4):276-80
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated sarcoidosis of upper respiratory tract--a description of 2 cases].
  • In sarcoidosis almost all organs can be involved but the disease most often affects the lungs and intrathoracic lymph nodes.
  • We present two cases of sarcoidosis limited to upper respiratory tract--a young woman with laryngeal sarcoidosis and recurrent throat pain, and a woman with disease of the sinuses and pharynx and clinical symptoms of chronic sinusitis poorly responsive to conventional treatment.
  • [MeSH-major] Laryngeal Diseases / drug therapy. Laryngeal Diseases / radiography. Sarcoidosis / drug therapy. Sarcoidosis / radiography. Sinusitis / drug therapy. Sinusitis / radiography
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged. Prednisone / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Sarcoidosis 2.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sinusitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785133.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Algar Algar FJ, Alvarez Kindelán A, Fuentes Vaamonde E, Salvatierra Velázquez A, Baamonde Laborda C, López Pujol FJ: [Simultaneaous bilateral pulmonary metastasectomy of carcinoma of the sweat glands]. Arch Bronconeumol; 2002 Aug;38(8):396-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Metastasectomía pulmonar bilateral simultánea de un carcinoma de glándulas sudoríparas.
  • Six years later she developed multiple bilateral lung metastases.
  • Nine nodes were resected from both lungs using a clamshell approach (bilateral transsternal, anterolateral thoracotomy).
  • After surgery, the patient received 6 cycles of adjuvant chemotherapy with cisplatin and 5-fluoruracil.
  • Three years after treatment, no intrathoracic recurrences had occurred and the patient was asymptomatic, with good quality of life.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sweat Gland Neoplasms
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Radiography, Thoracic. Thoracotomy. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12199923.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Kessel' MM, Agkatsev TV, Lazareva IaV, Perel'man MI: [Surgical treatment for tuberculosis of intrathoracic lymph nodes in children and adolescents]. Probl Tuberk Bolezn Legk; 2006;(5):33-5
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for tuberculosis of intrathoracic lymph nodes in children and adolescents].
  • Ninety-four children and adolescents with tuberculosis of intrathoracic lymph nodes (TITLN) were operated on.
  • Late diagnosis and long-term ineffective antituberculous therapy (chemotherapy lasted 2-3 years in 29.8% and 4-5 years in 19.1%) lead to the occurrence of complicated forms of TITLN in 34% of children.
  • Computed tomography (CT) reliably determines the extent, site, and phase of a tuberculous process, assesses the time course of changes in the efficiency of antituberculous therapy.
  • CT aids in defining the optimal time of surgical interventions.
  • Bilateral consecutive one-stage removal of affected lymph nodes is possible in children with bilateral TITLN.
  • [MeSH-major] Tuberculosis, Lymph Node / epidemiology. Tuberculosis, Lymph Node / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850920.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


Advertisement
4. Kevorkov NN, Gorovits GA, Bakhmet'ev SA: [Likopid in the complex immunomodulating treatment of patients with sarcoidosis of the lung and intrathoracic lymph nodes]. Ter Arkh; 2002;74(3):55-8
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Likopid in the complex immunomodulating treatment of patients with sarcoidosis of the lung and intrathoracic lymph nodes].
  • AIM: To examine the functional status of the immune system in patients with lung and intrathoracic lymph nodes sarcoidosis and to evaluate the efficiency of immunomodulation alone and in its inclusion in combined treatment of the disease.
  • RESULTS: The optimal result (as long as 3-year remission) was achieved in the first time diagnosed sarcoidosis who have not taken glucocorticoidal hormones.
  • CONCLUSION: The follow-up shows that addition of licopid is a compulsory component of immunotherapy in this disease; the efficiency of treatment is determined by its multimodality.
  • The courses of therapy should be repeated when immunological indices deteriorated.
  • [MeSH-major] Acetylmuramyl-Alanyl-Isoglutamine / analogs & derivatives. Acetylmuramyl-Alanyl-Isoglutamine / therapeutic use. Adjuvants, Immunologic / therapeutic use. Lymph Nodes / pathology. Sarcoidosis / drug therapy
  • [MeSH-minor] Adult. Drug Therapy, Combination. Glucocorticoids / adverse effects. Glucocorticoids / therapeutic use. Humans. Middle Aged. Oligopeptides / therapeutic use. Peptides / therapeutic use. Plant Preparations / therapeutic use. Recurrence. Sarcoidosis, Pulmonary / drug therapy. Sarcoidosis, Pulmonary / immunology. Thorax. Thymus Extracts / therapeutic use. Vitamins / therapeutic use

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11980125.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Glucocorticoids; 0 / Oligopeptides; 0 / Peptides; 0 / Plant Preparations; 0 / Thymus Extracts; 0 / Vitamins; 0 / glikopin; 0 / thymohexin; 53678-77-6 / Acetylmuramyl-Alanyl-Isoglutamine; 89492-35-3 / T-activin
  •  go-up   go-down


5. Baryshnikova LA, Sukhov VM, Mel'nik LE: [Tuberculin sensitivity in children at the time of diagnosis of tuberculosis of intrathoracic lymph nodes]. Probl Tuberk; 2001;(1):37-8
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tuberculin sensitivity in children at the time of diagnosis of tuberculosis of intrathoracic lymph nodes].
  • Trends in RM with 2 TU PPD-L were analysed in 71 children at the time of detection of tuberculosis of intrathoracic lymph nodes (TITLN).
  • Monotonous tuberculin tests represent the most frequent variant of tuberculin allergy at the time of TITLN diagnosis in children.
  • [MeSH-major] Tuberculin / immunology. Tuberculin Test. Tuberculosis, Lymph Node / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors. Sex Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11337780.001).
  • [ISSN] 0032-9533
  • [Journal-full-title] Problemy tuberkuleza
  • [ISO-abbreviation] Probl Tuberk
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Tuberculin
  •  go-up   go-down


6. Marchevsky AM, Gupta R, Kusuanco D, Mirocha J, McKenna RJ Jr: The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival. Hum Pathol; 2010 Nov;41(11):1536-43
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of isolated tumor cells and micrometastases in the intrathoracic lymph nodes of patients with lung cancer is not associated with decreased survival.
  • The prognostic role of small intrathoracic nodal metastases in primary patients with lung cancer has been controversial, and it is unclear how their presence should be used for pathologic staging and treatment planning.
  • The intrathoracic lymph nodes from 266 clinical stage I non-small cell carcinoma patients treated at Cedars Sinai Medical Center from 1992 to 2006 were evaluated with immunohistochemistry for keratin AE1/AE3 for the presence of isolated tumor cells and micrometastases, as defined by American Joint Commission on Cancer criteria, correlated with survival using the Kaplan-Meier method and analyzed with power analysis.
  • The English literature from 1995 to 2008 was reviewed to identify best available evidence regarding the prognostic value of isolated tumor cells and micrometastases detected with various immunohistochemistry and molecular methods in non-small cell carcinoma patients.
  • Isolated tumor cells and micrometastases were detected in 8 and 67 of 4148 lymph nodes, respectively, and their presence was not significantly associated with survival.
  • Power analysis showed that 3060 cases followed up for 60 months would be needed to achieve 80% power in a study designed to detect survival differences between patients with negative nodes and micrometastases.
  • Meta-analysis of 835 non-small cell carcinoma patients reported in 13 studies showed scanty data to evaluate patients with isolated tumor cells, no significant association between micrometastases and survival and significant data heterogeneity.
  • Current best evidence suggests that non-small cell carcinoma patients should probably not be "upstaged" in the presence of isolated tumor cells and micrometastases.
  • There is no data demonstrating survival benefits for patients treated with adjuvant chemotherapy and/or radiation therapy because of the presence of small nodal metastases.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. California / epidemiology. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Rate. Thorax

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Hum Pathol. 2011 Aug;42(8):1209-10; author reply 1210-1 [21663942.001]
  • (PMID = 20656322.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


7. Ivanovskiĭ VB, Nasorina RN, Ostroumova OM, Alekseeva DIu, Loshchinskaia NN: [Steroidal leukocytosis and immediate results of treatment in patients with sarcoidosis]. Probl Tuberk Bolezn Legk; 2006;(4):39-41
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Steroidal leukocytosis and immediate results of treatment in patients with sarcoidosis].
  • The occurrence of steroidal leukocytosis at early stages of an observation may, to a certain extent, serve an objective criterion for predicting the pronounced immediate results of treatment in first detected patients with sarcoidosis (that of intrathoracic lymph nodes and the lung in particular) and thus makes it possible to judge the adequacy of therapy in the inpatient setting.
  • When steroidal leukocytosis is absent, it is necessary to differentiately decide whether it is expedient to correct a hormonal therapy regimen in order to achieve the optimal results of its efficiency.
  • [MeSH-major] Anti-Inflammatory Agents / adverse effects. Leukocytosis / chemically induced. Prednisone / adverse effects. Sarcoidosis, Pulmonary / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lung / radiography. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813059.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


8. Foley RJ, Metersky ML: Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration; 2008;75(2):211-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
  • Sarcoidosis is a systemic granulomatous disease of unknown etiology, in which the lungs and intrathoracic lymph nodes are predominant sites of involvement.
  • Treatment of sarcoidosis-associated pulmonary hypertension has traditionally focused on the initiation of systemic corticosteroids, but has had inconsistent results.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Endothelin-1 / antagonists & inhibitors. Hypertension, Pulmonary / drug therapy. Sarcoidosis, Pulmonary / complications. Sulfonamides / therapeutic use
  • [MeSH-minor] Hemodynamics / drug effects. Humans. Male. Middle Aged. Respiratory Function Tests

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 S. Karger AG, Basel
  • (PMID = 16293957.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Endothelin-1; 0 / Sulfonamides; Q326023R30 / bosentan
  •  go-up   go-down


9. Ovsiankina ES, Gubkina MF, Kobulashvili MG, Panova LV: [Chemotherapy for tuberculosis in children and adolescents: problems and ways of their solution]. Probl Tuberk Bolezn Legk; 2006;(8):26-9
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for tuberculosis in children and adolescents: problems and ways of their solution].
  • Treatment of 329 patients aged 4-17 years who had first detected tuberculosis was analyzed.
  • The clinical pattern is mainly represented by infiltrative, focal tuberculosis and tuberculosis of intrathoracic lymph nodes (94.5%) and, in single cases, by other forms of tuberculosis.
  • Treatment was performed according to regimens I and III.
  • The time of abacillation is 1-2 months shorter than positive X-ray changes.
  • Microbiological monitoring methods should be primarily used to evaluate the initial combination of chemotherapy.
  • The active application of pathogenetic treatment modalities that promote the acceleration of reparative processes (physiotherapy in particular) generated the necessity of using 3 antituberculous agents in the phase of treatment continuation.
  • [MeSH-major] Antitubercular Agents / therapeutic use. Guidelines as Topic. Tuberculosis, Pulmonary / drug therapy
  • [MeSH-minor] Adolescent. Algorithms. Child. Child, Preschool. Drug Hypersensitivity / epidemiology. Drug Hypersensitivity / etiology. Female. Humans. Male. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002054.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


10. Fouzas I, Sotiropoulos GC, Sgourakis G, Drühe N, Wohlschlaeger J, Molmenti EP, Broelsch CE, Lang H: Five-year survival after monotherapy for hepatocellular carcinoma in the setting of cirrhosis. Transplant Proc; 2008 Nov;40(9):3204-5
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of recurrence were the intrathoracic lymph nodes in the first case, and lungs in the second case.
  • Treatment of recurrence included chemotherapy in the first case and local resection in the second case.
  • Both patients died at 98 and 64 months postoperation (ie, 17 and 16 months, respectively, after the diagnosis of the recurrence).
  • Currently, 11 patients are alive with a median survival of 70 months (range, 63-144 months).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Liver Transplantation / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Survival Rate. Survivors. Time Factors. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010235.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


11. Mitinskaia LA, Elufimova VF, Iukhimenko NV, Chernousova LN, Abdullaev RIu, Dem'ianenko NV, Baenskiĭ AV: [Diagnosis of latent primary intrathoracic tuberculosis of respiratory system in the phase of calcification in children]. Probl Tuberk Bolezn Legk; 2004;(1):16-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of latent primary intrathoracic tuberculosis of respiratory system in the phase of calcification in children].
  • The paper shows the latent activity of newly diagnosed intrathoracic tuberculosis in the phase of calcification in children: clinical and X-ray changes, tuberculin sensitivity (Manteaux test), the presence of Mycobacterium tuberculosis (MBT) in the sputum and blood (cultivation, bacterioscopy, polymerase chain reaction PCR), the blood levels of acute-phase reagents: haptoglobin and alpha 1-protease inhibitor (alpha 1-PI), immunological parameters, tuberculosis antibodies (TAb), and MBT antigen.
  • Ninety children were examined before treatment.
  • Twenty-five children (Group 1) were found to have single minor calcified masses in one group of intrathoracic lymph nodes or in the lung.
  • Thirty-five children (Group 2) had multiple lymph nodes or foci in the lung in the phase of consolidation and calcification.
  • Thirty children (Group 3, controls) were diagnosed as having intrathoracic tuberculosis in the phase of infiltration.
  • Thus, MBT and TAb were revealed in 90% of the children in Group 3 and in 52.9 and 76.0% in Groups 1 and 2, respectively.
  • There were signs of intoxication in 80 and 88% and a hyperergic Mantoux reaction in 44.0 and 43.3%, respectively.
  • Thus, children with newly diagnosed respiratory tuberculosis in the phase of calcification should be regarded as having the signs of tuberculosis activity, followed up as Group I patients, and prescribed chemotherapy for 3-6 months or more, depending on the extent of the process.
  • [MeSH-major] Calcinosis / diagnosis. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Lymph Node / diagnosis. Tuberculosis, Pleural / diagnosis. Tuberculosis, Pulmonary / diagnosis

  • Genetic Alliance. consumer health - Tuberculosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15137138.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


12. Antoine M: [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment]. Rev Pneumol Clin; 2007 Jun;63(3):183-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment].
  • [Transliterated title] Qu'apporte l'immunohistochimie à la prise en charge du cancer bronchique? De la morphologie au diagnostic et au traitement.
  • We detail here the contribution of IHC to the classification of lung cancer: small-cell lung cancer and other neuroendocrine tumors, basaloid carcinoma, large-cell carcinoma.
  • Using IHC techniques, pathologists can now determine with certainty that an intrathoracic adenocarcinoma is primary or secondary.
  • The distinction is less clear for large-cell carcinoma or squamous-cell carcinoma, or for tumors with a pleural or mediastinal presentation.
  • By demonstrating the presence of carcinomatous cells within the neighboring structures (pleura) or lymph nodes, IHC contributes to lung cancer staging, particularly when there are few of these elements morphologically difficult to distinguish.
  • Finally, IHC contributes to prognosis (proliferation markers, differentiation markers) or prediction of therapeutic response (chemotherapy or targeted therapies).
  • IHC studies may also be requested in a forensic setting, for example to demonstrate that the lung cancer observed in a patient exposed to asbestosis is primary.
  • Other morphological techniques such as hybridization in situ or molecular biology techniques will further complete the histological diagnosis in the future.
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / analysis. Forecasting. Humans. Lymph Nodes / pathology. Lymphoma / pathology. Mediastinal Neoplasms / pathology. Melanoma / pathology. Neoplasm Staging. Neuroendocrine Tumors / pathology. Pleural Neoplasms / pathology. Prognosis. Sarcoma / pathology. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675942.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Parra ER, Canzian M, Saber AM, Coêlho RS, Rodrigues FG, Kairalla RA, de Carvalho CR, Capelozzi VL: Pulmonary and mediastinal "sarcoidosis" following surgical resection of cancer. Pathol Res Pract; 2004;200(10):701-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary and mediastinal "sarcoidosis" following surgical resection of cancer.
  • Previous reports indicate that enlarged hilar and mediastinal lymph nodes caused by sarcoid-like reactions may develop after curative resection of cancer, and their presence does not necessarily denote neoplastic recurrence.
  • In this study, we describe two patients who had resected lung and gastric cancer and who later developed pulmonary interstitial infiltrate, concurrent with progressive mediastinal lymphadenopathy initially thought to be caused by intrathoracic dissemination of their cancer.
  • Thus, it is important to recognize this clinical pattern when pulmonary infiltrates develop after complete treatment of cancer in an otherwise relapse-free patient and to encourage lung or lymph node biopsy in these particular settings in order to confirm a sarcoid-like reaction, thereby avoiding unnecessary chemotherapy for presumed tumor recurrence.
  • [MeSH-minor] Aged. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Granuloma / pathology. Humans. Lymph Nodes / pathology. Male. Middle Aged. Thoracic Surgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15648607.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


14. Baltayiannis N, Anagnostopoulos D, Bolanos N, Tsourelis L: Thoracoscopy, bronchoscopy and mediastinoscopy in the staging of lung cancer. J BUON; 2002 Apr-Jun;7(2):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopy, bronchoscopy and mediastinoscopy in the staging of lung cancer.
  • PURPOSE: To estimate the benefit of Video-Assisted Thoracoscopy (VAT) in the staging of patients with lung cancer.
  • PATIENTS AND METHODS: Between October 1998 and January 2001 VAT was used in 250 patients with histologically proven lung cancer.
  • RESULTS: As a result of VAT 30 patients were upstaged and spared a thoracotomy receiving neo-adjuvant chemotherapy at that point.
  • In 40 patients the procedure was converted into an open thoracotomy and a curative resection was performed during the same session.
  • The remaining 180 patients were deemed inoperable and they received chemotherapy and radiation treatment.
  • It was especially useful in assessing the extent of invasion of various thoracic structures amenable to surgical removal "en block" with the tumor, and in differentiating simple contact of the tumor with an intrathoracic structure from tumor invasion.
  • In addition, it allowed access and sampling of lymph nodes in spaces not easily accessible by mediastinoscopy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577278.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Hölscher AH, Schröder W, Bollschweiler E, Beckurts KT, Schneider PM: [How safe is high intrathoracic esophagogastrostomy?]. Chirurg; 2003 Aug;74(8):726-33
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How safe is high intrathoracic esophagogastrostomy?].
  • [Transliterated title] Wie sicher ist die hoch intrathorakale Osophagogastrostomie?
  • The surgical results of transthoracic en bloc esophagectomy and high intrathoracic esophagogastrostomy performed on 109 consecutive patients are presented.
  • Adenocarcinoma was present in 59 patients, squamous cell carcinoma in 45 patients, and other neoplastic lesions of the esophagus in 5 patients: 29.5% of the patients received neoadjuvant radiochemotherapy or chemotherapy alone.
  • On average 33 lymph nodes were dissected from each specimen.
  • Nine patients (8.2%) developed anastomotic leakage.
  • Six of these nine patients were discharged after rethoracotomy and reanastomosis ( n=3) or endoscopic treatment with fibrin glue ( n=3).
  • Only 2 of 103 discharged patients (1.9%) underwent postoperative endoscopic bougienage two or three times because of an anastomotic stenosis.
  • High intrathoracic esophagogastrostomy is a safe anastomosis, which nevertheless requires diligent postoperative management.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Endoscopy. Female. Hospital Mortality. Humans. Lymph Node Excision. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Care. Postoperative Complications. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12928793.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Matsubara T, Ueda M, Kaisaki S, Kuroda J, Uchida C, Kokudo N, Takahashi T, Nakajima T, Yanagisawa A: Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus. Cancer; 2000 Nov 1;89(9):1869-73
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of initial lymph node metastasis from carcinoma of the thoracic esophagus.
  • BACKGROUND: Most surgeons consider esophageal carcinoma with lymph node involvement a systemic disease.
  • However, it is possible that the disease may be localized in the earlier phases of lymphatic metastasis.
  • The distribution of involved lesions in the initial phase of lymph node metastasis has not been thoroughly investigated yet.
  • METHODS: Among 329 patients that underwent curative (R0 International Union Against Cancer [UICC]) esophagectomy with systematic mesoesophageal dissection, 51 cases of patients with only 1 involved lymph node (solitary involvement) were retrospectively investigated and compared with patients with multiple involved lymph nodes.
  • The regional lymph nodes were divided into the thoracocervical junction group (lower deep cervical and recurrent nerve lymph nodes), perigastric group, and intrathoracic group.
  • RESULTS: Lymph node involvement was limited to a solitary lymph node in 46% of lymph node positive patients with esophageal carcinoma confined to the wall (T1 and T2, UICC) and in 17% of lymph node positive patients with cancer that invaded the extramural layer (T3 and T4, UICC).
  • Of patients with solitary involvement, 82% had a positive thoracocervical junction or perigastric lymph node.
  • The 5-year survival rate in solitary involvement cases was 61%, and 65% when solitary involvement was not intrathoracic.
  • Most of the 5-year survivors had involvement of a thoracocervical junction or perigastric lymph node and had not received systemic chemotherapy.
  • CONCLUSIONS: Solitary involvement was not rare and not directly associated with a disseminated disease.
  • Systematic dissection of the regional lymph nodes including thoracocervical junction and perigastric groups is recommended for resectable esophageal carcinoma at this time.
  • However, less extensive dissection may be performed in selected cases if the sentinel lymph node concept proves valid.
  • [MeSH-major] Esophageal Neoplasms / pathology. Lymphatic Metastasis
  • [MeSH-minor] Esophagectomy. Humans. Lymph Node Excision. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Rate. Thorax

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 11064342.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


17. Vasil'ev VI, Sedyshev SKh, Radenska-Lopovok SG, Logvinenko OA, Simonova MV, Aleksandrova EN, Safonova TN, Fadienko GR, Varlamova EIu, Nasonov EL: [Renal insufficiency due to interstitial nephritis in sarcoidosis]. Ter Arkh; 2009;81(12):67-71
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present their experience in diagnosing and treating interstitial nephritis with the development of chronic renal failure in a patient with generalized sarcoidosis, by involving the intrathoracic and peripheral lymph nodes, liver, spleen, subcutaneous fat, lung, as well as with the severe salivary and lachrymal gland lesions that imitate the clinical picture of Schogren's disease.
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Methylprednisolone / administration & dosage. Methylprednisolone / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20481054.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


18. Erokhin VV, Kornilova ZKh, Alekseeva LP: [The specific features of the detection, clinical manifestations, and treatment of tuberculosis in the HIV-infected]. Probl Tuberk Bolezn Legk; 2005;(10):20-8
HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The specific features of the detection, clinical manifestations, and treatment of tuberculosis in the HIV-infected].
  • The present study has explored the specific features of the detection, clinical manifestations, and treatment of tuberculosis (TB) in 425 patients with TB and HIV infection.
  • According to the time of joining the infections, the patients with TB and HIV infection are divided into 2 basic groups:.
  • 1) HIV infection is primary, TB develops at any stage of HIV infection and 2) TB is primary, HIV injections joins different forms of TB at its any stage.
  • In the pattern of clinical forms of tuberculosis in Group 1, there are prevalent forms of primary tuberculosis with lesion of intrathoracic and peripheral lymph nodes (12.8%), acutely progressive disseminated and miliary tuberculosis of the lung and extrapulmonary systems and organs (49%), among them, meningitis accounts for 4%, lesions of the liver, spleen, kidney, and other organs form 17%.
  • The proportion of TB/HIV patients with drug abuse (65%), hepatitis B and C (47%), and nervous and mental diseases is extremely high, which makes these patients more hazardous to the healthy population.
  • The efficiency of treatment for TB and HIV infection is satisfactory.
  • Continuous therapy for 4 months or more provides positive clinical and X-ray changes in most patients; bacterial isolation ceases in 75%, and decay cavities close in 44% of cases.
  • Abacillation and cavity closures have been observed in 76.3 and 38% and 47 and 14% of cases in Groups 1 and 2, respectively.
  • Six-eight-month therapy with first-line drugs in combination with reserve ones in patients with pulmonary TB and HIV infection is well tolerated and highly effective.
  • A decision on the duration of anti-TB treatment for the HIV infected should be taken into account the program resources and the probability of refusing long-term therapy in 50% of cases.
  • In patients with HIV/TB, the rates are higher than those in patients with TB/HIV and are 19.2 and 14.5%, respectively.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Antitubercular Agents / therapeutic use. HIV. Tuberculosis / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Radiography, Thoracic. Tuberculin Test

  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318255.001).
  • [ISSN] 1728-2993
  • [Journal-full-title] Problemy tuberkuleza i bolezneĭ legkikh
  • [ISO-abbreviation] Probl Tuberk Bolezn Legk
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


19. Meo A, Cassinerio E, Castelli R, Bignamini D, Perego L, Cappellini MD: Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. Int J Lab Hematol; 2008 Oct;30(5):425-31
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In some other conditions, such as myeloid metaplasia, polycythaemia vera or chronic myeloid leukaemia, EH is due to a clonal disorder of haematopoiesis that enables progenitor cells to escape from the marrow and lodge in other organs.
  • EH usually involves the liver, spleen and lymph nodes or it can be paravertebral, intrathoracic, pelvic.
  • Treatment options are still controversial and limited, including hypertransfusion regimen, surgical treatment, radiotherapy and hydroxyurea (HU).
  • We describe intrathoracic and symptomatic pelvic EH masses in a 48-year-old woman and intrathoracic bilateral masses causing respiratory insufficiency with pleural effusion in a 42-year-old male, both affected by thalassaemia intermedia.
  • Both patients showed a clinical improvement with hydroxyurea therapy and occasional blood transfusions.
  • [MeSH-major] Hematopoiesis, Extramedullary / drug effects. Hydroxyurea / therapeutic use. Nucleic Acid Synthesis Inhibitors / therapeutic use. beta-Thalassemia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046318.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nucleic Acid Synthesis Inhibitors; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 57
  •  go-up   go-down


20. Aboulafia DM: The epidemiologic, pathologic, and clinical features of AIDS-associated pulmonary Kaposi's sarcoma. Chest; 2000 Apr;117(4):1128-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike classical forms of the disease, AIDS-associated KS is a multicentric entity that frequently involves lymph nodes and the GI tract.
  • The exact incidence of intrathoracic KS in patients with AIDS is unknown.
  • Before the advent of highly active antiretroviral therapy (HAART), pulmonary KS had been reported in approximately 10% of patients with AIDS, 25% of patients with cutaneous KS, and in roughly 50% of postmortem examinations of patients with AIDS, KS, and respiratory infections.
  • An aggressive diagnostic evaluation of patients who have this condition is essential because chemotherapy and radiation therapy may provide significant palliation, particularly if used in conjunction with HAART.
  • The pathology and pathogenesis of KS is also reviewed, along with the clinical and radiographic presentation, diagnosis, and management of pulmonary KS.


21. Dapri G, Himpens J, Cadière GB: Minimally invasive esophagectomy for cancer: laparoscopic transhiatal procedure or thoracoscopy in prone position followed by laparoscopy? Surg Endosc; 2008 Apr;22(4):1060-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive esophagectomy for cancer: laparoscopic transhiatal procedure or thoracoscopy in prone position followed by laparoscopy?
  • This retrospective comparative study aimed to compare two minimally invasive techniques for esophagectomy: transhiatal laparoscopy with intrathoracic or cervical anastomosis (group A) and right thoracoscopy in prone position followed by laparoscopy and left cervicotomy (group B) performed by the same surgeon (G.B.C.).
  • The operative time, perioperative blood loss, intensive care and total hospital stays, peri- and postoperative morbidity, in-hospital mortality, number of lymph nodes dissected, and survival were the outcome measures.
  • METHODS: Between April 1999 and August 2005, 24 patients (group A) and 15 patients (group B) underwent minimally invasive esophagectomy for cancer in the authors' department.
  • Their median age was 61 years in group A and 61 years in group B.
  • One patient (group A) and two patients (group B) received only neoadjuvant chemotherapy, and three patients (group A) received only neoadjuvant radiotherapy.
  • RESULTS: The median operative time was 300 min (range, 240-420 min) in group A and 377 min (range, 240-540 min) in group B (nonsignificant difference [NS]).
  • The median perioperative bleeding was 325 ml (range, 100-800 ml) in group A and 700 ml (range, 100-2,400 ml) in group B (NS).
  • The postoperative medical complications totaled three in group A and six in group B.
  • The postoperative surgical complications included one hemoperitoneum, one pneumothorax, five anastomotic leaks, and two recurrent laryngeal nerve paralyses in group A and two tracheal necroses, four anastomotic leaks, one colic fistula, and three recurrent laryngeal nerve paralyses in group B.
  • The median intensive care unit (ICU) stay was 5 days (range, 2-70 days) for group A and 5 days (range, 1-180 days) for group B (NS).
  • The median hospital stay was 12 days (range, 7-98 days) for group A and 14 days (range, 7-480 days) for group B (p = 0.05).
  • The median number of mediastinal/periesophageal lymph nodes was 3 (range, 1-10) for group A and 4 (range, 2-13) for group B (NS), and the median number of celiac/perigastric lymph nodes was 11 (range, 2-31) for group A and 10 (range, 3-22) for group B (NS).
  • After a median follow-up period of 42.4 months (range, 2-84 months) for group A and 19.1 months (range, 1.5-34 months) for group B, 12 patients in group A died after a median period of 22 months (range, 2-55 months), and 7 patients in group B died after a median time of 15 months (range, 1.5-23 months).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Length of Stay / statistics & numerical data. Lymph Node Excision. Male. Middle Aged. Minimally Invasive Surgical Procedures. Postoperative Complications. Prone Position. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):306-13 [11465217.001]
  • [Cites] Arch Surg. 2000 Aug;135(8):920-5 [10922253.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4 [15570202.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1170-6; discussion 1170-6 [15464465.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):486-94; discussion 494-5 [14530720.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):428-33 [16391954.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Dec;120(6):1093-6 [11088031.001]
  • [Cites] Surg Endosc. 2004 May;18(5):812-7 [15216864.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):218-23 [10064749.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Apr;123(4):661-9 [11986593.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):232-40 [17245176.001]
  • [Cites] Surg Laparosc Endosc. 1995 Feb;5(1):1-5 [7735533.001]
  • [Cites] Br J Surg. 1994 Feb;81(2):236-8 [8156345.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1667-70 [17332960.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):402-6; discussion 406-7 [16863737.001]
  • [Cites] J Am Coll Surg. 2004 Jan;198(1):42-50 [14698310.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):293-7 [10064770.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):215-22 [12067683.001]
  • [Cites] World J Surg. 2001 Feb;25(2):189-95 [11338021.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):593-6 [11515902.001]
  • [Cites] Am J Surg. 2005 Jul;190(1):69-74 [15972176.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1308-9 [16897282.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):16-20 [17031742.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):654-62 [7487213.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):836-51 [52764.001]
  • [Cites] J Am Coll Surg. 2006 Jul;203(1):7-16 [16798482.001]
  • [Cites] J R Coll Surg Edinb. 1992 Feb;37(1):7-11 [1573620.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):629-32 [15026898.001]
  • [Cites] Surgery. 2004 Oct;136(4):917-25 [15467679.001]
  • [Cites] Ann Thorac Surg. 2001 Dec;72(6):1918-24; discussion 1924-5 [11789772.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):902-13 [14644277.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):277-81 [15780563.001]
  • [Cites] J Am Coll Surg. 1997 Jun;184(6):630-6 [9179120.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Feb;14(1):13-6 [15035838.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1681-6 [16960662.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Arch Surg. 1997 Sep;132(9):943-7; discussion 947-9 [9301605.001]
  • (PMID = 18071806.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W: Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys; 2001 Sep 1;51(1):56-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
  • PURPOSE: Tumor response after nonoperative lung cancer therapy is traditionally evaluated by bidimensional measurement of maximum tumor diameters.
  • The purpose of this analysis is to investigate whether tumor largest dimension (based on RECIST [Response Evaluation Criteria In Solid Tumors]), bidimensional tumor product, and volume correlate with each other in evaluating tumors of patients with locally advanced non-small-cell lung cancer (NSCLC).
  • In addition, the pace of locally advanced NSCLC volumetric response over time, as well as the prognostic value of tumor size, was assessed in this report with software-assisted evaluation of sequential tumor measurement.
  • METHODS AND MATERIALS: Patients with locally advanced NSCLC treated with thoracic radiotherapy (RT) with or without chemotherapy were included, if the following were available: a pretreatment computed tomography (CT) simulation and at least two follow-up diagnostic thoracic CT scans taken at our institution after 1996 that were available in Dicom format for electronic transfer of images from diagnostic radiology to a computer terminal with commercial statistics software (AcQsim/CMS Focus).
  • Primary lung tumor and grossly involved lymph nodes were contoured manually on pre-RT axial images and on all follow-up CT scans.
  • Tumor/lymph node largest dimensions, bidimensional products (BP), and volumes were measured using the same software.
  • The median thoracic RT dose was 62.4 Gy (range: 50.0-69.6), and all patients had a Karnofsky performance status > or =80.
  • Chemotherapy (mostly carboplatin/paclitaxel) was given to 17 patients.
  • Failure rates were as follows: in-field, 36% (8/22); intrathoracic (lung nodules, effusion, pleura), 55% (12/22); and distant, 50% (11/22).
  • Overall median survival time (MST) is 27.3 months.
  • At 24 months, 79% of patients with a tumor volume < or =124.0 cc (n = 18) had locally controlled tumors, vs. 0% of patients with tumor volumes >124.0 cc.
  • At the same time point, 93% of patients with BP < or =40 cm(2) were locally controlled, vs. 0% of those with BP > 40 cm(2); 100% of patients with tumor dimensions < or =7.5 cm were locally controlled, vs. 40% of those with dimensions >7.5 cm.
  • The partial responses in our series (assessed as the best response obtained during observation period) were as follows: 4 patients assessed based on either dimension only, product only, or volume only; 15 partial responses based on dimension or product; 16 partial responses based on volume alone; 3 cases of no tumor response, based on dimension or product; and 2 cases based on tumor volume alone.
  • (1) The response of locally advanced NSCLC to nonoperative therapy is a slow process, with tumor volumes reaching their nadir several months after treatment. (2) Smaller initial tumor size, as measured by largest tumor dimension, bidimensional product, or tumor volume, is associated with better local control and survival than larger initial measurements. (3) Any of the three tumor measurements (largest dimension, bidimensional product, or volume) can be used as a reliable tool in assessing lung cancer response to nonoperative therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiography. Lung Neoplasms / radiotherapy. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11516851.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mouroux J, Venissac N, Alifano M: Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. Ann Thorac Surg; 2001 Nov;72(5):1698-704
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer.
  • BACKGROUND: This study seeks to assess the safety and usefulness of combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of patients with lung cancer.
  • Indications for this combined approach included inconclusive findings from imaging techniques concerning locoregional extension and resectability; possible involvement of different structures not accessible to a single procedure; and failure to obtain histologic diagnosis by a single technique.
  • RESULTS; Histologic diagnosis was obtained in 6 patients without preoperative histologic typing.
  • In 3 patients, in contrast with preoperative imaging studies, combined thoracoscopy and mediastinoscopy showed the resectability of the primary tumor and the absence of metastatic mediastinal lymph nodes.
  • In 3 other patients prevascular lymph nodes metastases were found.
  • They underwent neoadjuvant chemotherapy; at subsequent operation, a complete resection was possible.
  • In the remaining four cases combined exploration proved definitive contraindications for operation (recognition of oat-cell carcinoma, n = 2; T4 status, n = 1; T3N2, n = 1).
  • Both the extent of primary tumor and the possible intrathoracic spread may be exhaustively evaluated.
  • In patients with left lung cancer a complete exploration of the aortopulmonary window is possible.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Mediastinoscopy / methods. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11722067.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement